BIOS

Presenters & Panelists

Emily Alexander, J.D., is the Director of U.S. Regulatory Affairs in the Biologics Strategic Development group at AbbVie, Inc., where she leads the company's biotherapeutic regulatory efforts in the United States. AbbVie is a global biopharmaceutical company formed in January 2013, following its separation from Abbott. AbbVie supports the entry of safe and effective biosimilars around the world, and Ms. Alexander works with a cross-functional team dedicated to ensuring that international, national, and state biosimilar laws and policies are focused on patients and based in sound science. Ms. Alexander regularly speaks and writes on issues related to FDA's implementation of its biosimilar authority, with a particular focus on naming and labeling. Prior to joining AbbVie, she was an attorney in the Food & Drug practice group at Covington & Burling LLP's Washington, D.C. office. She holds a law degree from the University of Virginia School of Law and a Bachelor of Arts from Purdue University.

Geoffrey Eich, M.B.A., is an Executive Director, R&D Policy at Amgen Inc., where he leads a global, cross-functional scientific and policy team dedicated to the topic of biosimilars. He is a member of Amgen's biosimilar development team. Mr. Eich is accountable for Amgen's worldwide policy advocacy, aspects of strategic planning related to biosimilars, and integration of scientific, policy, regulatory, communications and business activities. Previously, Mr. Eich was the founding Director of Amgen's Regulatory Biosimilar Team, with significant focus on establishment and participation in the U.S. biosimilar pathway as authorized by Congress in 2010 in the Biologics Price Competition and Innovation Act (BPCIA). Mr. Eich's team has been able to synthesize the scientific and technical aspects of regulatory policies and guidelines for biologics with experiences from Europe, Asia, Latin America and the multifaceted aspects of the U.S. health care environment. Mr. Eichholds a Bachelors of Science degree from the U.S. Naval Academy at Annapolis and a Masters of Business Administration from the University of Maryland. He is a Paul Harris Fellow and is married with two children.

Aaron (Ronny) Gal, Ph.D., is the Senior Research Analyst covering the specialty pharmaceutical industry at Sanford C. Bernstein, providing research and investment insights on specialty and generic pharmaceutical stocks to institutional clients around the world. His work is recognized in third-party surveys, including those conducted by Institutional Investor and Greenwich Associates. Prior to joining Bernstein, Dr. Gal spearheaded Canon's business development in life sciences. He also spent six years with the Boston Consulting Group, advising clients in the pharmaceutical and healthcare delivery sectors. Dr. Gal was awarded a Ph.D. from the Massachusetts Institute of Technology and holds a B.Sc. from Emory University.

Gustavo Grampp, Ph.D., is a Director of R&D Policy at Amgen, where he leads external affairs related to biosimilars in the United States. Prior to this role, he was a member of Amgen's regulatory policy function assessing and advocating for science-based implementation of biologics policies. In this capacity, he was also responsible for worldwide regulatory agency interactions, technical strategy and submissions related to Amgen's biosimilars development program. Before his engagement on biosimilars, Dr. Grampp led manufacturing process development teams responsible for development and technology transfer of biologics processes for several of Amgen's novel biologic

BIOS

medicines into manufacturing sites around the world. He also managed quality professionals providing technical and strategic oversight to both pre and post-approval commercialization projects including numerous comparability exercises. Dr. Grampp earned his bachelor's degree in Chemical Engineering at the University of Wisconsin and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.

Helen Hartman, Ph.D. is Director, Worldwide Regulatory Strategy, at Pfizer. Dr. Hartman started her career in the biotech industry in the areas of cardiovascular and metabolic research. Since joining Pfizer, she has held positions of increasing responsibility within worldwide regulatory strategy. She is currently a global regulatory lead for biosimilars at Pfizer and has extensive working knowledge of the biosimilar regulatory landscape. She has presented at multiple biosimilar conferences and was a member of Biotechnology Industry Organization's (BIO's) Science & Regulatory Biosimilars Working Group, which commented on the FDA's biosimilars Draft Guidances. Dr. Hartman received her Ph.D. from the Department of Molecular and Cellular Biology at the University of Pennsylvania.

Aaron Kesselheim, M.D., J.D., M.P.H., is an Assistant Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women's Hospital (BWH). At BWH, he leads the Program on Regulation, Therapeutics, and Law, an interdisciplinary research core focusing on the effects of intellectual property laws and regulatory policies on drug and medical device development, the FDA approval process, and the costs, availability, and evidence-based use of therapeutics both domestically and in resource-poor settings. He is Board Certified in Internal Medicine, and serves as a primary care physician at the Phyllis Jen Center for Primary Care at BWH. Dr. Kesselheim has published over 100 peer-reviewed articles and book chapters in the medical, law, and policy literatures. His research is supported by the Greenwall Foundation, the Agency for Healthcare Research and Quality, and a Robert Wood Johnson Investigator Award in Health Policy Research. He has testified before Congress on pharmaceutical policy and medical device regulation, and served as a consultant for the NIH, FDA, Institute of Medicine, USPTO, and numerous state government offices.

Bruce Leicher, J.D., is Senior Vice President and General Counsel at Momenta Pharmaceuticals, Inc., an innovator biotechnology company engaged in the development of complex generic products, biosimilars, interchangeable biologics, and novel products. Mr. Leicher has advised biotechnology companies for over 20 of his more than 30 years of legal experience. Mr. Leicher is a frequent lecturer on biotechnology law. Before joining Momenta, he served in senior legal positions at Altus Pharmaceuticals, Inc., Antigenics, Inc., Millennium Pharmaceuticals, Inc., Genetics Institute, Inc., and Wyeth. In private practice, he served as the Co-Chair of the Life Sciences Practice Group at Hill and Barlow and was an attorney at Hale and Dorr and Butler & Binion. Mr. Leicher served as a law clerk to the Honorable Thomas F. Hogan in the U.S. District Court for the District of Columbia after receiving his J.D. from Georgetown Law Center and his B.A. from the University of Rochester.

Angela G. Long, M.S., is Senior Vice President, Global Alliances and Organizational Affairs and Executive Secretariat, Council of Experts for USP. Ms. Long's primary roles at USP are alliances with pharmacopoeias, regulatory authorities and health ministries, and stakeholders throughout the world; Executive Secretariat of the Council of Experts and its Expert Committees; and leadership of Healthcare Quality Standards including USP's Nomenclature, Safety and

BIOS

Labeling, Compounding, and Therapeutic information and Formulary Support Expert Committees. Ms. Long is the lead representative to the World Health Organization and is also the lead representative for pharmacopoeial harmonization. A long-time employee of USP, Ms. Long has had progressively responsible positions within the organization. Prior to her current role, she served as Vice President, Volunteer and Organizational Affairs, where she managed overall support and decision-making processes for the USP Council of Experts. Ms. Long joined USP in 1990. During a brief time away from USP, she operated RightInsight, Inc., a communications company that served clients such as the American Pharmacists Association, the Food and Drug Law Institute, the American Association of Colleges of Pharmacy, the American Society of Clinical Pharmacology and Therapeutics, and USP. She has a bachelor's degree from the University of Maryland and a master's degree in pharmacy (pharmaceutical outcomes and policy/drug regulatory affairs) from the University of Florida School of Pharmacy in Gainesville, Florida.

Bruce Lott is vice president of State Government Relations for Mylan, one of the world's leading generic and specialty pharmaceutical companies. In that position, he leads the company's state government affairs activities and serves as a liaison on state issues with other generic companies and industry partners. Bruce also has primary responsibility for biologics policy activities globally. Prior to joining Mylan in 2007, Bruce served as vice president of State Affairs for the Generic Pharmaceutical Association (GPhA). In that capacity, he oversaw state government affairs activities for GPhA and coordinated efforts for its member companies. Bruce has more than 20 years of legislative, political and communications experience in Washington, D.C., including 12 years of state government relations work in the pharmaceutical industry. Before joining GPhA in 2003, he was senior director of public affairs for the Pharmaceutical Research and Manufacturers of America (PhRMA). At PhRMA, he served as a spokesman on state and legal issues, developed and implemented communications strategies on a variety of matters, and managed the association's state-based public relations consultants and activities. Bruce previously served as communications director to U.S. Senator Trent Lott of Mississippi; legislative assistant for health issues to U.S. Senator Sheila Frahm of Kansas; director of communications and marketing for the law and lobbying firm Preston, Gates, Ellis and Rouvelas Meeds, and as director of communications/station relations for PBS television's The NewsHour with Jim Lehrer. Bruce is a native of Mississippi and a graduate of the University of Mississippi.

Alan M. Lotvin, M.D. is Executive Vice President of Specialty Pharmacy for CVS Caremark. In this role, Dr. Lotvin has overall responsibility for the company's Specialty Pharmacy business, a rapidly growing division of the company's pharmacy benefits management business. He is focused on driving specialty pharmacy strategy and identifying opportunities for growth and innovation in this fast-growing segment of the health care industry. Dr. Lotvin is a published author with an extensive clinical background and experience in the health care services, pharmaceutical benefit management and specialty pharmacy industries. Prior to joining CVS Caremark, Dr. Lotvin was President and Chief Executive Officer of ICORE Healthcare, a Magellan Health Services company. Previously, he has held roles as President and Chief Operating Officer of M|C Communications, a leading medical education provider. After leaving clinical practice, Dr. Lotvin served in various senior management roles at Medco Health Solutions, including serving as President of Medco Specialty Pharmacy Services. Dr. Lotvin began his career as an interventional cardiologist in the New York metropolitan area with a faculty appointment at College of Physicians and Surgeons at Columbia University. Dr. Lotvin holds a Master's Degree in Medical Informatics from Columbia University and a Medical Degree from the State University of New York Health Sciences Center in Brooklyn.

BIOS

Jessica Mazer, Esq. is the Assistant Vice President of State Affairs for the Pharmaceutical Care Management Association (PCMA). In this position, she is responsible for coordinating lobbying efforts and providing advocacy support to the Association's members in all 50 states, the District of Columbia, and Puerto Rico. She also oversees all state legislative and regulatory tracking. Prior to joining PCMA, she served as a Legislative Attorney for the National Alliance for Model State Drug Laws. In this position, she researched and analyzed legislation related to over seventy drug and alcohol issues. Ms. Mazer also provided assistance in the drafting of state legislation, local ordinances, and model laws for governors, attorneys general, and state legislators. In addition, she served as a law clerk for the Honorable John J. Farley, III at the United State Courts of Appeals for Veterans Claims. Ms. Mazer holds a Bachelor of Science degree in Biology from George Mason University and a Juris Doctor from Hofstra University School of Law.

Mark McCamish, M.D., Ph.D., is the Global Head of Biopharmaceutical Development for Sandoz International, a Division of Novartis. He leads research and development of all biologics at Sandoz Biopharmaceuticals. His responsibilities include leadership involving selection of the target, cloning, technical development, scale-up, pre-clinical and clinical development, and interfaces with regulatory authorities worldwide. He is a senior executive with extensive therapeutic and commercial experience in global pharmaceutical and biotechnology companies. Previously, Dr. McCamish was Senior VP and Chief Medical Officer at three biotechnology companies and held senior positions at Amgen and Abbott Laboratories. He has held professorships and maintained academic practices at the University of California, Davis, and The Ohio State University. Dr. McCamish earned his bachelor's and master's degrees in exercise physiology from the University of California, Santa Barbara. His Ph.D. is in human nutrition from Penn State University, and his M.D. is from the University of California, Los Angeles. Dr. McCamish is Board Certified in Internal Medicine and Nutrition and Metabolism, and he is licensed as a physician and surgeon in California. He has published broadly in several therapeutic areas in multiple journals.

Steven B. Miller, M.D., M.B.A., is Senior Vice President and Chief Medical Officer for Express Scripts, Inc. He has been actively involved in development of Express Scripts' clinical programs supporting the use of generic pharmaceuticals and specialty medications. He is a leader in the promotion of legislation to create a pathway at the FDA for regulation of biogenerics and biosimilars. Previously, Dr. Miller served as Vice President and Chief Medical Officer at Barnes-Jewish Hospital/Washington University School of Medicine in St. Louis. After receiving his medical degree from the University of Missouri, Kansas City, Dr. Miller trained as a Fellow in Pathology and Research at the University of Alabama, Birmingham, and as the William J. and Dorothy Fish Kerr Fellow in cardiology at the University of California, San Francisco. From 1983 through 1988, he was a house officer and faculty member at the University of Colorado Health Science Center in Denver. In 1988, he was appointed a Nephrology Fellow at Washington University, where he remains a faculty member. Dr. Miller also received his MBA at The Olin School of Business at Washington University in St. Louis. He frequently speaks internationally, and he has published over 80 scientific articles.

Tina Morris, Ph.D., is Vice President, Biologics and Biotechnology, USP-NF in the Global Science and Standards Division at USP, which she joined in 2003. She coordinates all standard-setting activities in the division related to biologics and biotechnology for the U.S.-based compendia and manages the scientific staff responsible for the relevant Expert Committees, the development of biological reference materials, and the biologics laboratory at USP Headquarters. Before joining

BIOS

USP, Dr. Morris' industrial experience includes major biotech companies in the areas of analytical development, especially mass spectrometry, and recombinant protein characterization. Dr. Morris is the holder of several United States patents in the areas of virology and mass spectrometry assay development. She is the author of many publications in peer-reviewed journals and a frequent invited speaker at national and international scientific conferences. Dr. Morris earned her Ph.D. degree in molecular virology at the Medical University of Lübeck, Germany and her M.S. and B.A. degrees in biology at the University of Oldenburg, Germany.

Leigh Purvis, M.P.A., is a Senior Strategic Policy Advisor with AARP's Public Policy Institute. Her work focuses on a variety of prescription drug and mental health-related issues, with a particular emphasis on prescription drug pricing, biologic drugs, and prescription drug coverage under Medicare. She also co-authors the Public Policy Institute's Rx Price Watch reports, which track price trends for prescription drugs widely used by older Americans. Prior to coming to AARP, Ms. Purvis worked for the American Psychological Association. She received her M.P.A with a concentration in health administration and policy from George Mason University and her B.S. in Psychology from the University of Mary Washington. Ms. Purvis also holds a certificate in gerontology from the University of Washington.

Sumant Ramachandra, M.D., Ph.D., M.B.A., brings 20-plus years of health care experience and strong leadership abilities to his role as Senior Vice President and Chief Scientific Officer of Hospira, Inc. Dr. Ramachandra has made career leading scientific advancements for some of the industry's largest pharmaceutical companies, including Merck, Pharmacia, Pfizer, and Schering-Plough. As an R&D business leader, he set in motion several therapy programs that would benefit patients living with cancer. He was also responsible for formulating innovative strategies and executing R&D plans that resulted in successful U.S. FDA approvals. Dr. Ramachandra's award-winning work is widely recognized through publications, such as the PharmaVOICE 100, which recognizes top leaders in the health sciences, as well as *Diversity MBA Magazine's* "Top 100 Under 50 Diverse Executive Leaders" and *Crain's Chicago Business'* "40 Under 40." He earned a bachelor's degree in biochemistry from Rutgers University, graduating with high honors. Dr. Ramachandra then pursued a combined M.D./Ph.D. degree from the University of Medicine and Dentistry-New Jersey Medical School, receiving the University's Medal of Excellence and subsequently conducting his residency at the Harvard-affiliated Massachusetts General Hospital. Dr. Ramachandra also earned an M.B.A. at Wharton Business School.

Marissa Schlaifer, M.S., R.Ph., joined CVS Caremark as Head of Policy in April 2013. Based out of the CVS Caremark Washington, D.C., office, Marissa leads the team responsible for creating policy positions that help shape the laws and regulations impacting CVS Caremark business, and she also serves as a key contact with federal agencies. Marissa brings deep experience with policy analysis and issue advocacy, having spent ten years as Director of Pharmacy and Regulatory Affairs at the Academy of Managed Care Pharmacy (AMCP). Marissa brings experience in both the managed care pharmacy and community pharmacy segments of the profession as well as leadership experience in several pharmacy organizations. Prior to joining AMCP, Marissa was Healthy Outcomes Director at H-E-B Grocery Company, where she was responsible for disease management and health improvement programs, immunization programs and new business opportunities. Previously, Marissa worked for PacifiCare of Texas and Prescription Solutions as a clinical pharmacist, and for Eckerd Drug Company as pharmacy manager and a regional manager for managed care sales. She received her B.S. in Pharmacy and M.S. in Pharmacy Administration from The University of Texas

BIOS

at Austin College of Pharmacy. Marissa has been active in leadership positions within AMCP, the American Pharmacists Association and the Texas Pharmacy Association.

Emily Shacter, Ph.D., regulated therapeutic proteins at the FDA for 18 years, serving most recently as the Chief of the Laboratory of Biochemistry in CDER's Division of Therapeutic Proteins in the Office of Biotechnology Products. Prior to leaving the FDA in 2012, Dr. Shacter supervised the review of regulatory submissions for a wide range of novel and biosimilar protein products. She contributed to FDA policies and expectations for the manufacture, control, and analytical characterization of therapeutic proteins. Dr. Shacter received her Ph.D. in Biochemistry from Johns Hopkins University and carried out laboratory research on cell regulation, inflammation, protein oxidation, and cancer at the NIH and FDA for over 30 years. Dr. Shacter now works as an independent consultant through her business - ThinkFDA LLC.

Harry Travis, B.S. Pharm., M.B.A., is Vice President and General Manager for Aetna Specialty and Home Delivery Pharmacy. Mr. Travis is a senior executive with over 25 years' experience in operations, quality improvement, sales, marketing, and product development; primarily in specialty pharmacy, PBM, and pharma markets. He has been successful in entrepreneurial and turnaround situations, product launches, and acquisition integration. Mr. Travis has held senior management positions at Baxter Healthcare, Cardinal Health, and Accredo/Medco. He received his Bachelor of Science Degree in Pharmacy from the University of Pittsburgh School of Pharmacy and his M.B.A. from the Darden School at the University of Virginia.

Krystalyn Weaver, Pharm.D., serves as the Director of Policy and State Relations at the National Alliance of State Pharmacy Associations (NASPA). NASPA promotes leadership, sharing, learning, and policy exchange among state pharmacy associations and pharmacy leaders nationwide, and provides education and advocacy to support pharmacists, patients, and communities working together to improve public health. In her role at NASPA, Krystalyn works with the state pharmacy associations and NASPA's national partners to track, trend, and communicate health care policy information. She earned her Pharm.D. degree from the University of Toledo in Toledo, Ohio and completed a post-graduate residency in Association Management and Leadership with the American Pharmacists Association.

FTC Staff

Edith Ramirez was sworn in as a Commissioner of the Federal Trade Commission in April 2010 and became Chairwoman of the FTC in March 2013. At the FTC, Chairwoman Ramirez has focused on promoting competition and innovation in the technology and healthcare sectors, protecting underserved communities from deceptive and unfair practices, and safeguarding consumer privacy. Before joining the FTC, Chairwoman Ramirez was a partner in the Los Angeles office of Quinn Emanuel Urquhart & Sullivan, LLP, where she litigated complex business disputes, including intellectual property, antitrust, unfair competition, and advertising matters. She is a graduate of Harvard Law School, where she was an editor of the *Harvard Law Review*, and Harvard College.

Andrew I. Gavil is the Director of the Office of Policy Planning at the Federal Trade Commission, on leave from Howard University School of Law, where he has been a member of the faculty since 1989. He has

BIOS

written and spoken extensively in the United States and abroad on various aspects of antitrust law, policy, jurisdiction, and procedure. Mr. Gavil received his B.A. *magna cum laude* from Queens College of the City University of New York, and his J.D. from Northwestern University School of Law, where he was a member of the Law Review.

Tara Isa Koslov is Deputy Director of the FTC's Office of Policy Planning, a position she has held since March 2011. Her portfolio includes a broad range of competition and consumer protection issues. Ms. Koslov previously spent almost twelve years as an Attorney Advisor to three different FTC Commissioners (focusing primarily on competition issues), and also worked in one of the agency's merger enforcement divisions, following several years in private practice. She completed a three-year term as Editorial Co-Chair of the Antitrust Law Journal, having served on the editorial board for 15 years. Ms. Koslov earned her J.D. from Harvard Law School and an A.B. from Brown University.

Elizabeth A. Jex is an Attorney Advisor in the FTC's Office of Policy Planning where her expertise includes health care competition and regulation. She is one of the primary authors of the FTC's *Follow-On Biologic Drug Report* in 2009, work that earned her the agency's Paul Rand Dixon Award for its contribution to the FTC's mission. From 1990 to 2009, Ms. Jex was an attorney in the FTC's Bureau of Competition, where she investigated pharmaceutical, biotechnology, and medical device mergers, acquisitions, and intellectual property licensing agreements. Ms. Jex is a graduate of Williams College and earned her J.D. from Georgetown University Law Center.

Susan DeSanti is an attorney in the Western Regional Office of the FTC. Previously, she was the Director of Policy Planning at the FTC from April 1995 through June 2001, and from May 2009 through June 2012. She was also FTC Assistant General Counsel for Policy Studies from July 2001 through June 2006. In those roles, she was responsible for the development and drafting of several reports on competition policy issues, including global and high-tech competition, patents and competition, generic drug competition, and health care competition, among others. She also was responsible for the development of the *FTC/DOJ Competitor Collaboration Guidelines.* She joined the FTC in 1991 as an Attorney Advisor to Commissioner Dennis Yao, and subsequently served as the Director of Policy and Evaluation in the Bureau of Competition and Attorney Advisor to Chairman Robert Pitofsky. She served as Senior Counsel to the Antitrust Modernization Commission (AMC) from July 2006 through May 2007 and contributed to the development and drafting of the AMC's report. Prior to joining the FTC, she was a partner at Hogan and Hartson, and she was a partner at Sonnenschein Nath and Rosenthal from June 2007 through April 2009. She attended Boston University School of Law, where she was a member of the Law Review, graduating *cum laude* in 1981.

Meredyth Smith Andrus is an attorney with the Health Care Division of the FTC, Bureau of Competition. Prior to joining the FTC in September 2006, Ms. Andrus was an Assistant Attorney General in the Antitrust Division of the Maryland Office of the Attorney General. She has been in antitrust enforcement for twenty-five years, primarily in the health care field. Ms. Andrus has taken a prominent role in numerous multistate and joint federal/state investigations and prosecutions in the pharmaceutical industry. In an agency-wide investigation, Ms. Andrus led an FTC team of competition and consumer protection attorneys and economists prosecuting and settling a Medicare Part D dispute with pharmaceutical benefit manager and retail pharmacy, CVS Caremark. She earned her J.D. in 1985 from Cornell Law School, her B.A. in 1978 from Cornell University and her M.F.A. in dance in 1981 from Sarah Lawrence College. She is admitted to the bars of the State of Maryland, the U.S. District Court for the District

BIOS

of Maryland, the U.S. Court of Appeals for the Fourth Circuit, and the U.S. Supreme Court.

Karen Berg is the Coordinator for State/Federal Relations in the FTC's Bureau of Competition, serving as the Bureau's liaison with the offices of the various State Attorneys General and with NAAG. She divides her time between these duties and Hart-Scott-Rodino premerger compliance review and rulemaking. Prior to moving to the Premerger Notification Office in 1999, she was a staff attorney for ten years in the Bureau's Anticompetitive Practices litigation shop. Ms. Berg holds her B.A. and J.D. from the College of William and Mary in Virginia.

Erin E. Flynn joined the FTC's Bureau of Competition as an Honors Paralegal in October 2011. While at the FTC, she has worked on a variety of cases in the Healthcare, Mergers III, and Mergers IV shops within the Bureau of Competition. She also worked with the Office of Policy Planning in 2012 for the planning and execution of the FTC Pet Medications Workshop. Ms. Flynn received her B.A. in History and French from Providence College. She plans to continue working in public service and begin an advanced degree program in education in summer 2014.

Christopher Garmon is an Economist with the FTC's Bureau of Economics, where he currently specializes in the economic analysis of hospital and physician mergers and biologic pharmaceutical markets. He has worked on numerous hospital and physician merger investigations for the FTC (e.g., *Evanston Northwestern Healthcare/Highland Park Hospital; Inova Healthcare/Prince William Hospital; Providence Health/Spokane Cardiology/Heart Clinics Northwest*). Recently, he helped the FTC and the Department of Justice's Antitrust Division write guidelines for the antitrust review of Accountable Care Organizations established by the Patient Protection and Affordable Care Act of 2010. He has taught courses in industrial organization and other economic topics at Johns Hopkins University, Kenyon College, and the University of Florida. He received his Ph.D. in economics from the University of Florida in 1997.

Neal C. Hannan is an Attorney Advisor in the FTC's Office of Policy Planning, where he has focused on intellectual property and competition issues. Prior to working at the FTC, Mr. Hannan was an intellectual property litigator at Boies, Schiller & Flexner LLP. Before that, he served as a law clerk to the Hon. Daniel M. Friedman at the U.S. Court of Appeals for the Federal Circuit. Mr. Hannan is a graduate of Williams College and Columbia Law School.

Andrea J. Kelly joined the FTC in September 2011, as a Paralegal Specialist in the Office of the General Counsel. There, she worked on a wide variety of appellate litigation and legislative research projects, as well as the processing of Freedom of Information Act requests. Recently, Ms. Kelly has applied her experience in policy research to assist the Office of Policy Planning in its preparation for a number of upcoming workshops. She received her B.A. in Political Science from Providence College, with a minor in Economics.

Stephanie Wilkinson is an Attorney Advisor in the FTC's Office of Policy Planning, where she has worked on competition and consumer protection issues in healthcare markets. Ms. Wilkinson joined the FTC in 2001, and before joining OPP, she served as a staff attorney in the Bureau of Competition, where she investigated mergers involving a range of industries including pharmaceuticals, medical devices, laboratory services, high technology, and chemicals. Ms. Wilkinson earned her J.D. from William and Mary School of Law in 2001 and a B.A. from Vanderbilt University in 1996.

BIOS